$135 Million is the total value of Knoll Capital Management, LLC's 18 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $46,631,000 | +30.3% | 857,494 | 0.0% | 34.43% | +5.2% | |
| APLT | Applied Therapeutics Inc | $12,742,000 | +148.2% | 467,071 | 0.0% | 9.41% | +100.3% | |
| BX | Blackstone Group LP | $8,522,000 | +14.0% | 153,000 | 0.0% | 6.29% | -8.0% | |
| EIGR | Eiger Biopharmaceuticals Inc | $5,219,000 | +45.4% | 350,238 | 0.0% | 3.85% | +17.3% | |
| KBA | Kraneshares TRbosera msci ch | $3,138,000 | +9.3% | 96,000 | 0.0% | 2.32% | -11.8% | |
| LUMN | Centurylink Inc | $2,906,000 | +5.8% | 220,000 | 0.0% | 2.15% | -14.6% | |
| AVXL | Anavex Life Sciences Corp | $1,876,000 | -18.0% | 724,205 | 0.0% | 1.38% | -33.9% | |
| DOW | Dow Inc | $1,642,000 | +14.8% | 30,000 | 0.0% | 1.21% | -7.4% | |
| MTEM | Molecular Templates | $1,592,000 | +112.0% | 113,905 | 0.0% | 1.18% | +71.2% | |
| SNGX | Soligenix Inc. | $1,142,000 | +52.7% | 787,830 | 0.0% | 0.84% | +23.1% | |
| CTVA | Corteva Inc | $887,000 | +5.6% | 30,000 | 0.0% | 0.66% | -14.8% | |
| CATS | Catasys Inc | $702,000 | +3.5% | 43,034 | 0.0% | 0.52% | -16.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.